Scribe targets $96 million from Nasdaq IPO as Scholar Rock awaits site classification for apitegromab

Scribe, a gene-editing biotech, announced plans for a Nasdaq initial public offering that could raise roughly $96 million.

The company said it would price the shares at $14 each, which is the midpoint of the expected range, and expects net proceeds of about $96 million after expenses.

In a separate update, Scholar Rock is waiting for regulatory authorities to classify the site for its experimental therapy apitegromab, but no further details were provided.